SUPERNUS PHARMACEUTICALS INC

Supernus Pharmaceuticals secures 7‑year FDA exclusivity for Parkinson’s drug ONAPGO, boosting investor confidence and positioning the company for strong CNS pipeline growth.

Supernus (SUPN) trades near key technical support; its CNS drug pipeline and 200‑day SMA below price offer a buying angle for savvy investors.

Supernus Pharmaceuticals’ 2026 Q3 earnings call focuses on CNS‑disorder drugs, market cap $2.3B, and a $41.23 share price—find out the latest insights.